With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.36958-61-9,5-(Bromomethyl)-3-methylisoxazole,as a common compound, the synthetic route is as follows.
lodomethylcyclopropane (0.03 mL, 0.20 mmol) was added to a stirring mixture of N-(1 -cyanocyclopropyl)-N-[[3-[(2-methylthiazol-5-yl)methyl]-2,4-dioxo- 1H- quinazolin-6-yl]sulfonyl]acetamide (76 mg, 0.170 mmol) and potassium carbonate (92 mg, 0.66 mmol) in DMF (3 mL) and left to stir at room temperature for 16 h. Concentrated ammonia (100 muL) was added and the mixture heated to 40 C for 10 min. The mixture was allowed to cool and DCM (8 mL) and saturated aqueous ammonium chloride solution (8 mL) was added and the mixture stirred for 5 min. The DCM layer was isolated by passing through a hydrophobic frit and the aqueous layer washed with DCM (10 mL). The combined DCM extracts were concentrated under reduced pressure and purified by prep HPLC (low pH) yielding the desired product (8 mg, 0.017 mmol, 10%) as a white powder.This compound was prepared from 5-(bromomethyl)-3-methyl-1 ,2-oxazole (0.02 mL, 0.20 mmol) and N-(1 -cyanocyclopropyl)-N-[[3-[(2-methylthiazol-5-yl)methyl]-2,4- dioxo- 7H-quinazolin-6-yl]sulfonyl]acetamide (76 mg, 0.170 mmol) according to the method described in Example 399. This gave the desired product (10 mg, 0.020 mmol, 12%) as a white powder
36958-61-9, 36958-61-9 5-(Bromomethyl)-3-methylisoxazole 10607354, aIsoxazoles compound, is more and more widely used in various fields.
Reference£º
Patent; CANCER RESEARCH TECHNOLOGY LIMITED; MCGONAGLE, Alison E.; JORDAN, Allan; WASZKOWYCZ, Bohdan; HUTTON, Colin; WADDELL, Ian; HITCHIN, James R.; SMITH, Kate Mary; HAMILTON, Niall M.; (497 pag.)WO2016/92326; (2016); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem